Free Trial
NYSE:CPHI

China Pharma (CPHI) Stock Price, News & Analysis

China Pharma logo
$1.91 -0.07 (-3.54%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$1.93 +0.02 (+1.05%)
As of 05/2/2025 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About China Pharma Stock (NYSE:CPHI)

Key Stats

Today's Range
$1.88
$2.00
50-Day Range
$1.50
$29.49
52-Week Range
$1.20
$4.10
Volume
21,318 shs
Average Volume
65,686 shs
Market Capitalization
$6.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.

Receive CPHI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for China Pharma and its competitors with MarketBeat's FREE daily newsletter.

CPHI Stock News Headlines

Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
China Pharma announces 1-for-10 reverse stock split
China Pharma Holdings, Inc.
See More Headlines

CPHI Stock Analysis - Frequently Asked Questions

China Pharma's stock was trading at $23.00 at the start of the year. Since then, CPHI shares have decreased by 91.7% and is now trading at $1.91.
View the best growth stocks for 2025 here
.

China Pharma Holdings, Inc. (NYSE:CPHI) announced its quarterly earnings results on Wednesday, August, 15th. The company reported ($100.00) EPS for the quarter. The business had revenue of $3.17 million for the quarter. China Pharma had a negative trailing twelve-month return on equity of 63.93% and a negative net margin of 85.56%.

China Pharma shares reverse split on Tuesday, April 15th 2025. The 1-10 reverse split was announced on Friday, April 4th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 14th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of CPHI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that China Pharma investors own include iBio (IBIO), Biocept (BIOC), Micron Technology (MU), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), Tonix Pharmaceuticals (TNXP) and Bionano Genomics (BNGO).

Company Calendar

Last Earnings
8/15/2018
Today
5/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:CPHI
Employees
250
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-3,080,000.00
Pretax Margin
-85.56%

Debt

Sales & Book Value

Annual Sales
$4.53 million
Price / Cash Flow
N/A
Book Value
$0.70 per share
Price / Book
2.73

Miscellaneous

Free Float
15,918,000
Market Cap
$6.23 million
Optionable
Not Optionable
Beta
0.77

This page (NYSE:CPHI) was last updated on 5/4/2025 by MarketBeat.com Staff
From Our Partners